Mäenpää J, Ruskoaho H, Pelkonen O
Department of Pharmacology and Toxicology, University of Oulu, Finland.
Pharmacol Toxicol. 1989 May;64(5):446-50. doi: 10.1111/j.1600-0773.1989.tb00684.x.
The effects of five calcium antagonists, verapamil, diltiazem, nifedipine, darodipine and isradipine, on rat liver microsomal drug metabolism in vitro and in vivo were studied. All compounds prolonged hexobarbital-induced sleeping time in a dose-dependent manner (doses 3.0 and 30.0 mg/kg, except nifedipine 0.3 and 3.0 mg/kg) and inhibited cytochrome P450-dependent N-demethylation of aminopyrine in vitro in rat liver microsomes. The incubation of all compounds with microsomes resulted in the apparent formation of formaldehyde, suggesting either N- or O-demethylation. Diltiazem, isradipine and darodipine gave rise to a type I spectral change. Nifedipine seemed to produce a type II spectral change. A spectrum of verapamil changed from a type I to a type II as concentration increased. These results indicate that all calcium antagonists studied interact with P450 and are in vitro inhibitors of microsomal drug metabolism in the rat and the inhibition brings out pharmacokinetic drug-drug interactions in vivo.
研究了维拉帕米、地尔硫䓬、硝苯地平、达罗地平和平尼地平这五种钙拮抗剂对大鼠肝脏微粒体药物代谢在体内外的影响。所有化合物均以剂量依赖性方式延长了己巴比妥诱导的睡眠时间(剂量为3.0和30.0mg/kg,硝苯地平为0.3和3.0mg/kg除外),并在体外抑制了大鼠肝脏微粒体中细胞色素P450依赖性的氨基比林N-去甲基化。所有化合物与微粒体孵育均导致明显的甲醛形成,提示可能发生N-或O-去甲基化。地尔硫䓬、平尼地平和达罗地平引起I型光谱变化。硝苯地平似乎产生II型光谱变化。随着浓度增加,维拉帕米的光谱从I型转变为II型。这些结果表明,所研究的所有钙拮抗剂均与P450相互作用,并且在体外是大鼠微粒体药物代谢的抑制剂,这种抑制在体内引发药代动力学药物-药物相互作用。